Subtype-Specific Mutations Drive Relapse Risk in Most Common Childhood Leukemia
Researchers at St. Jude Children's Research Hospital have identified specific genetic mutations in B-cell acute lymphoblastic leukemia that correlate with higher relapse risks. These findings could allow doctors to personalize treatment intensity for pediatric patients based on their tumor's genetic profile.
Why it matters
Improving the ability to predict leukemia relapse could significantly increase survival rates and reduce the need for overly aggressive treatments in low-risk cases.
Caption: (L to R) Co-first author Yuan Feng, PhD, corresponding author Xiaotu Ma, PhD, and co-first author Hanxia Li, PhD, all of the St. Jude Department of Computational Biology.
Newswise — (MEMPHIS, Tenn. - November 02, 2026 ) Some cases of the most common childhood cancer, B-cell acute lymphoblastic leukemia (B-ALL), return after treatment - and genetic changes present from the start may help explain why. Scientists at St. Jude Children's Research Hospital and Seattle Children's Hospital, in collaboration with the Children's Oncology Group, found that mutations in a patient's original tumor can be associated with relapse risk, and that these changes differ by leukemia subtype. The findings, published today in Blood , could help researchers better estimate and adjust for relapse risk before treatment begins.
Also covering this story
One other newsroom covered this event. We read that version too.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in